Global Recombinant Protein Market

Recombinant Protein Market Size, Share, Growth Analysis, By Product (Cytokines & Growth Factors, Antibodies), By Application (Drug Discovery & Development, Biopharmaceutical Production), By Region - Industry Forecast 2026-2033

Report ID: SQMIG35H2039 | Region: Global | Published Date: December, 2025
Pages: 165 |Tables: 66 |Figures: 75

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Recombinant Protein Market size was valued at USD 2.53 Billion in 2024 and is poised to grow from USD 2.71 Billion in 2025 to USD 4.73 Billion by 2033, growing at a CAGR of 7.2% during the forecast period (2026–2033).

    There are several dominant players in the recombinant protein business. Several strategic activities, such as mergers, partnerships, alliances, new product launches, acquisitions, and collaborations, are being implemented by the firms to help them increase their international competitiveness. For instance, in February 2021, In order to determine the best antigen dosages for the Phase 3 evaluation of its adjuvanted recombinant protein COVID-19 vaccine candidates, Sanofi and GSK have begun a new Phase 2b trial with 720 individuals who are 18 years old & older. 'Bio-Techne (US) ', 'Thermo Fisher Scientific Inc. (US) ', 'Merck KGaA (Germany) ', 'Danaher Corporation (US) ', 'Abnova Corporation (Taiwan) ', 'BioLegend Inc (US) ', 'Bio-Rad Laboratories, Inc. (US) ', 'BPS Bioscience, Inc. (US) ', 'Enzo Biochem Inc. (US) ', 'GenScript (China) ', 'Miltenyi Biotec B.V. & Co. KG (Germany) ', 'Proteintech Group, Inc. (US) ', 'Sino Biological Inc. (China) ', 'ACROBiosystems Group (US) ', 'Aviva Systems Biology Corporation (US) ', 'Sartorius CellGenix GmbH (Germany) ', 'Icosagen (US) ', 'Neuromics (US) ', 'ProSpec-Tany TechnoGene Ltd. (Israel) ', 'ProteoGenix S.A.S (France)'

    Over the projected time frame, the antibody segment is projected to expand at an exponential rate. This process has attracted attention in recent years and several businesses have embraced it for use in a variety of applications. After a selection procedure for antibodies with the necessary qualities, the genes can be introduced into an expression system, and the antibodies can be generated in large amounts.

    In 2022, North America accounted for the largest share of the global market, and this trend is expected to continue during the forecast. The rising prevalence of chronic diseases, growing R&D investments, increased research and government incentives, and the presence of manufacturing companies in the U.S. are all factors contributing to North America's market development. 

    Related Reports

    Recombinant Vaccines Market
    Buy Now GET FREE SAMPLE
    Recombinant DNA Technology Market
    Buy Now GET FREE SAMPLE
    Protein Engineering Market
    Buy Now GET FREE SAMPLE
    Recombinant Coagulation Factors Market
    Buy Now GET FREE SAMPLE
    Alternative Protein Market
    Buy Now GET FREE SAMPLE
    Protein Therapeutics Market
    Buy Now GET FREE SAMPLE
    Protein Chip Market
    Buy Now GET FREE SAMPLE
    Microbial Protein Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Recombinant Protein Market

    Report ID: SQMIG35H2039

    $5,300
    BUY NOW